Be the first person to write a business review for Dyadic International, Inc.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. Elusys Therapeutics company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim has shown to be effective in combatting infections caused by anthrax up to 48 hours after exposure. When administered prior to exposure, the drug has proven to be 100% effective in preventing infections. Another drug candidate, Staph A Heteropolymer, targets staphylococcus infections, which have become increasingly prevalent and resistent to treatment. Other Elusys products target non-Hodgkin's lymphomas, lupus, and deep vein thrombosis.

EMD Serono develops a potpourri of prescription pharmaceuticals used for the treatment of neurological, metabolic, and fertility disorders and diseases such as multiple sclerosis (MS), lupus, and HIV. The Massachusetts-based company conducts research and development programs in the US and markets products that include Gonal-f, Luveris, Ovidrel, Rebif, and Zorbtive in the US and Canada. The company has manufacturing and marketing agreements with other pharmaceutical firms, including Pfizer (MS) and CuraScript (fertility). EMD Serono is the North American operating subsidiary of Merck Serono S.A..

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.